EvaluatePharma - Daiichi Sankyo - Worldwide

Daiichi Sankyo

All Financial Data in US $ (mln)Show in reporting currency

Worldwide

Overview

Company News

Appellate Court Affirms U.S. District Court Decision in Favor of Daiichi Sankyo Patent for Benicar(R), Benicar HCT(R), and AZOR(R)
Daiichi Sankyo (September 10, 2010)

Daiichi Sankyo Receives Approval to Manufacture and Market Inavir(R) Influenza Antiviral Inhalant for Treatment in Japan
Daiichi Sankyo (September 10, 2010)

Revision of Earnings Forecasts
Daiichi Sankyo (August 31, 2010)

Notice of Daiichi Sankyo Organizational Restructuring to be Effective October 1, 2010
Daiichi Sankyo (August 27, 2010)

Daiichi Sankyo Files for Approval to Manufacture and Market AMG 162 (Denosumab) in Japan
Daiichi Sankyo (August 25, 2010)

Notice of Details of the Stock Options (Stock Acquisition Rights)
Daiichi Sankyo (August 19, 2010)

BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
BioMarin Pharmaceutical (August 17, 2010)

Announcement on Change in Ranbaxy Executive Leadership
Daiichi Sankyo (August 12, 2010)

Daily Market Movers (4 Aug 2010)

(August 05, 2010)

Notice of Commencing Open Offer for Shares in Zenotech Laboratories Limited
Daiichi Sankyo (August 04, 2010)

Displaying 10 out of a possible 800 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile



Profile	Daiichi Sankyo is a major Japanese pharmaceutical company and is the new name for Sankyo following its merger with Daiichi Pharmaceutical in SEP 2005.
Listed or Private Company	Listed
Company Classification	Regional Major; Generic
Company Website	Website

Full Company Profile Information

EventAnalyzer - Last Key Event


Closing Price DateClosing Price Date	EventAnalyzer Note	Market Cap (US $m)	Change (%)	Change (+$m)
8/4/2010	4 Aug: Company plans to buy a 20% stake in Zenotech Laboratories for up to Rs.782m ($17m), or Rs.113.62 ($2.46) per share.	12,358	-2.1%	-262

Top 3 Products (Worldwide Sales 2007/08)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2007	2008	2008
1	Benicar/Olmetec	olmesartan medoxomil	Angiotensin II antagonists	1,718²	2,001³	+16%
2	Mevalotin	pravastatin sodium	Anti-hyperlipidaemics	600⁴	546⁵	-9%
3	Cravit	levofloxacin	Anti-bacterials	416⁶	429⁷	+3%

Note: Shaded Cells⁸

RX Sales Chart

Daiichi Sankyo	Data		Growth
	2007	2008	2008
Revenues By Segment
Pharmaceuticals
Pharmaceuticals Sales (In-depth)
Rx & OTC Pharmaceuticals
Prescription (Rx) Pharmaceuticals	6,399	7,373	+15%

Therapy Area Focus in 2008

Daiichi Sankyo
	2008
WW Rx & OTC Sales By Therapy Area
Main Categories
Blood	320
Cardiovascular	3,602
Endocrine	51
Gastro-Intestinal	78
Genito-Urinary	227
Musculoskeletal	595
Oncology & Immunomodulators	151
Respiratory	216
Sensory Organs	10
Systemic Anti-Infectives	512
Various	339
Other Rx & OTC Pharma	1,428

EvaluatePharma® Coverage of Marketed and Pipeline Products


	Product Count
Daiichi Sankyo ⁹	237

2009 Product Sales analysis
2009 Pharmaceutical Sales
2009 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases


EP Vantage - last 6 months

Therapeutic focus - Anti-thrombotics face a period of change (July 26, 2010)

Event - Brilinta has questions to answer (July 21, 2010)

Therapeutic focus - Late stage set backs sharpen focus on earlier lung cancer candidates (March 31, 2010)

GenVec failure highlights gene therapy risks (March 30, 2010)

Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXXX XX ¥XX:
X) +XX.X XXXXXXX XXXXX XX XXX (XXX XXXX XX XXX XXXX).
X) +XX.X XXXXXXX XXXXX XX XXXXXX (XXX XXXX XX XXX XXXX).
X) +XX.X XXXXXXX XXXXX XX XXXXX (XXX XXXX XX XXX XXXX).
X) +XX.X XXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXXXXX XXXXXX XXXXXX XXXX XXXXXXX (XXX XXXX – XXX XXXX) (XX XXX XXXX):
XXXXXXXX XXXXXXX XXX XXX XXXX XXXXXXXX XX XXX XXX XXXXX XXXXXXXX (XXXXXX. -XX%), XXXXX XXXX XXXXXXXX XX XXX XXXXXXXX XX XXX XXXXXXXXXXXXXXXX XXXXXXX XX XXXXXXXX XXXX XXX XXXXXX.

XXXXXX: XXXXXX XXXXXXXXXXXX XXXXXX XXXX XX-X (XX XXX XXXX), XXXX XX:
XXXXXXX XXX XXXXXXX XXX XXX XXXXXXX XX X X.X. XXXXXXXXXXX XX XXXXXX XXXXXX XXXX XXXXXXX XX XXXX. XXXXXX XXX XXXX X XXXXXXX XXXXXXXXXXXX XXX XXXXXXXXXX XXXX XXXXXX XXXXX XX XXXX XXX XXXXXXXXX XXXXXXX XXX XXXXXXXX XX XXXXXXXXXX XXXXXXX XXXXXXXX XX XXXXXXX. X XXXXX XXXXX XX XXXX XXXXXXX XXX XXXXXXXXX XX XXXXX XXXX.

XXXXXXXX XX ¥XX:
X) +XX.X XXXXXXXX (XXXXX) XXXXX.
X) +X.X (€XXX) XXXXXXXXX XXXXX XX XXXXXX XX XXXXXXX XXXXXX XXXXXX XXXX (XXX).

XXXXXXX XXXXXXX:

XXXXXX: XXXXXXX XXXXXX XXXXXX XXXX XXXXXXX (XXX XXXX – XXX XXXX) (XX XXX XXXX):
XXXXXXXX XX "XXXX XXXXX", X XXXXX-XXXXX XXXXX XXX XXXXXXXX, XXXXXXXXXXXX XXXX XXX XXXXXXXXXX, XXXXXXXXX XXXXXXX XXX XXXXXXXXXXX XX XX XXXXXXXXXX XX XXX XXXXXXXX. XXXXXXX, XXXXX XXXXXXXX XXX XX XXXXXXXXX XXXXXXXXX XXXX XXXXX XXXXX XXX XXXXXXXX.

XXXXXXXX XX ¥XX:
X) +XX.X XXXXXXXX (XXXXX) XXXXX.
X) +X.X (€XXX) XXXXXXXXX XXXXX XX XXXXXX XX XXXXXXX XXXXXX XXXXXX XXXX (XXX).

XXXXXXX XXXXXXX:

XXXXXX: XXXXXXX XXXXXX XXXXXX XXXX XXXXXXX (XXX XXXX – XXX XXXX) (XX XXX XXXX):
XXXXXXX XXX XXXXXXXX XX XXX XXXXXX XX XXXXXXXXXXXXX XXXXX XXXX XXXXX XXXXXXX XXXX XXXXXXXXX XX XXXXXXXXX XXXXXXXXX, XXXXX XX XXXXXXXXX XXXXXXXX XXX XX XXXXXXXXXX XXXXXXXXXXXXX XX XXXXXXXX XXX XXXXXXXXXXX XXXX XXXXX XXXXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXXXXX XXXXXX XXXXXX XXXX XXXXXXX (XXX XXXX – XXX XXXX) (XX XXX XXXX):
XXXXXXX XXX XXXXXX XX XXXXXXXXX XXX XXXXXXXXX, XXX XXXXXX XX XXXXXX XXXXXXXXXXXXX XX XXXXXXXXXX XXX XX XXX XXXXXX XXXXXXXXXXX XXXXXXXXXX XXX XXXXXX XXX XXXXXXXXXXXXX XXXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXXXXX XXXXXX XXXXXX XXXX XXXXXXX (XXX XXXX – XXX XXXX) (XX XXX XXXX):
XXXXX XXXXXXX XXX XX XXX XXXXXXXX XXXXXX XXXXXXXXX XXX XXX XXXXX XXXXXXXX. XXXXXXX, XXXXXX XXXXXXX XXXXXXXXXXX XXX XXXXXXXXXX XXX XXXXXX XXX XXXXXXXXXXXXX XXXXXXX, XXX XXXXXXXXXX XXX XXXXXX XXXXX XXXX XXXX XXX XXXXXX XX X XXXXX XXXX XXXX X XXXXXXXXXX.

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.